AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8826769 — intervention group
Group type: EXPERIMENTAL
Intervention: Music video intervention
Number of subjects: 96
Study 8826769 — intervention group
Group type: COMPARATOR
Intervention: Rest period control group
Number of subjects: 96
Study 1443245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline and interpersonal psychotherapy
Number of subjects: 73
Study 1443245 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance conditions
Number of subjects: 73
Study 1443245 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline conditions
Number of subjects: 73
Study 6364909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol, 375 mg/d
Number of subjects: 53
Study 6364909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30678674 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving cognitive behaviour therapy (PSCBT) plus treatment as usual (TAU)
Number of subjects: 22
Study 30678674 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 22
Study 30052729 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg by intravenous infusion every 2 weeks
Number of subjects: 371
Study 30052729 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (paclitaxel 80mg/m2 on days 1, 8, and 15 or irinotecan 150mg/m2 on days 1 and 15)
Number of subjects: 371
Study 30052729 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy
Number of subjects: 371
Study 27334658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (open-label)
Number of subjects: 233
Study 27334658 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks (blinded)
Number of subjects: 233
Study 27334658 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID (blinded)
Number of subjects: 233
Study 25294104 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 72
Study 25294104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training towards smoking cues
Number of subjects: 72
Study 25294104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training away from smoking cues
Number of subjects: 72
Study 25294104 — intervention group
Group type: COMPARATOR
Intervention: Control training (CBM)
Number of subjects: 72
Study 25294104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer task (modified Stroop test of smoking‐related cognitive bias)
Number of subjects: 72
Study 25294104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective mood and cigarette craving
Number of subjects: 72
Study 23627026 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurarinol (600 mg intravenous drip once a day for one month, followed by 200 mg oral capsule three times a day)
Number of subjects: 69
Study 23627026 — intervention group
Group type: COMPARATOR
Intervention: Silybin meglumine tablet (same dosage as treatment group)
Number of subjects: 69
Study 23120733 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar cautery
Number of subjects: 80
Study 23120733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 80
Study 23120733 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency monopolar cautery
Number of subjects: 80
Study 23120733 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency bipolar cautery
Number of subjects: 80
Study 23120733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile I (QI) 100 mg/dl
Number of subjects: 234
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile II (QII) 130 mg/dl
Number of subjects: 234
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile III (QIII) 162 mg/dl
Number of subjects: 234
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile I (QI) 100 mg/dl after adjustment for confounders
Number of subjects: 234
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile II (QII) 130 mg/dl after adjustment for confounders
Number of subjects: 234
Study 17870226 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile III (QIII) 162 mg/dl after adjustment for confounders
Number of subjects: 234
Study 15830722 — intervention group
Group type: EXPERIMENTAL
Intervention: 3A Ofteno (Diclofenac sodium mixed with Sophisen)
Number of subjects: 0
Study 15830722 — intervention group
Group type: EXPERIMENTAL
Intervention: Modusik-A Ofteno (Cyclosporine-A mixed with Sophisen)
Number of subjects: 0
Study 12458653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 690
Study 12458653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + HCTZ 12.5 mg
Number of subjects: 690
Study 12458653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + HCTZ 25 mg
Number of subjects: 690
Study 12458653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + other antihypertensive +/- HCTZ (12.5 or 25 mg)
Number of subjects: 690
Study 12458653 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 690
Study 10378365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch reconstruction with preservation of the duodenal passage
Number of subjects: 0
Study 10378365 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction with a small jejunal pouch
Number of subjects: 0
Study 10378365 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y-reconstruction without pouch
Number of subjects: 0
Study 8724536 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day intravenous infusions of 2-CdA
Number of subjects: 41
Study 8724536 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day courses of 2-CdA
Number of subjects: 41
Study 8724536 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent 2-hour infusions of 2-CdA
Number of subjects: 41
Study 8724536 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous 24-hour infusion of 2-CdA
Number of subjects: 41
Study 1770128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin 200 micrograms four hourly for 21 days
Number of subjects: 33
Study 1770128 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin 500 micrograms twice a day for 7 days, followed by 500 micrograms daily for 14 days
Number of subjects: 33
Study 1770128 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin 500 micrograms three times a day for 7 days
Number of subjects: 33
Study 1770128 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 33
Study 1770128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 33
Study 6761186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg
Number of subjects: 450
Study 6761186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg + Dipyridamole 75 mg three times daily
Number of subjects: 450
Study 6761186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 29796934 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow-derived mesenchymal stromal cells (BM-MSCs) by intrathecal infusion (1×10^6 cells/kg body weight, four infusions once a week)
Number of subjects: 118
Study 29796934 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 118
Study 28973311 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with bevacizumab, prescribed dose escalated from 18 to 22 Gy, single dose of bevacizumab given prior to SRS and continued until progression.
Number of subjects: 9
Study 26919233 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing (measured by Pain Catastrophizing Scale)
Number of subjects: 25
Study 24687108 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition and interaction training (SCIT) with social mentoring
Number of subjects: 55
Study 24687108 — intervention group
Group type: COMPARATOR
Intervention: Social mentoring only
Number of subjects: 55
Study 23198926 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument set A
Number of subjects: 14
Study 23198926 — intervention group
Group type: COMPARATOR
Intervention: Instrument set B
Number of subjects: 14
Study 23198926 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-cutting task (using scissors and graspers)
Number of subjects: 14
Study 23198926 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg transfer task (using 2 graspers)
Number of subjects: 14
Study 23198926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligature loop task (using 1 grasper and 1 pretied ligature loop)
Number of subjects: 14
Study 20937186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI < 17 kg/m(2)
Number of subjects: 979
Study 20937186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 979
Study 20937186 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BMI from baseline to Year 1
Number of subjects: 979
Study 17563195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessments using the Penn State Worry Questionnaire
Number of subjects: 0
Study 17563195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessments using the Beck Depression Inventory‐‐II
Number of subjects: 0
Study 17563195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessments
Number of subjects: 0
Study 17071161 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (45 minutes, 5 days per week for 12 months)
Number of subjects: 115
Study 17071161 — intervention group
Group type: COMPARATOR
Intervention: Control group (once-weekly, 45-minute stretching sessions)
Number of subjects: 115
Study 11823389 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued antidepressants before surgery (Group A, n=40)
Number of subjects: 80
Study 11823389 — intervention group
Group type: COMPARATOR
Intervention: Discontinued antidepressants 72 hr before surgery (Group B, n=40)
Number of subjects: 80
Study 10449701 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm tip electrode catheter
Number of subjects: 104
Study 10449701 — intervention group
Group type: COMPARATOR
Intervention: 4-mm tip electrode catheter
Number of subjects: 104
Study 8545533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ)
Number of subjects: 48
Study 8545533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (FL)
Number of subjects: 48
Study 8545533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study 1971991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) (3.4 g/d)
Number of subjects: 33
Study 1971991 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid (14.3 g/d)
Number of subjects: 33
Study 1971991 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (9.2 g/d)
Number of subjects: 33
Study 375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 0.2 g three times daily
Number of subjects: 30
Study 375690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30636639 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 40
Study 30636639 — intervention group
Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (ML)
Number of subjects: 40
Study 28675897 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Health Management (IHM) program for 1 year
Number of subjects: 67
Study 28675897 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of daily lifestyle
Number of subjects: 67
Study 25466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato sauce (with refined olive oil)
Number of subjects: 0
Study 25466100 — intervention group
Group type: COMPARATOR
Intervention: Raw tomatoes
Number of subjects: 0
Study 25466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato sauce (without refined olive oil)
Number of subjects: 0
Study 22874090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based pain management program (8 weeks)
Number of subjects: 28
Study 22874090 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 28
Study 21081764 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 44
Study 21081764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19686525 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 202
Study 19686525 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 202
Study 19686525 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM) and Methadone
Number of subjects: 202
Study 17464273 — intervention group
Group type: EXPERIMENTAL
Intervention: Back education program (13 hours over 2 school years)
Number of subjects: 398
Study 17464273 — intervention group
Group type: COMPARATOR
Intervention: Obligatory curriculum (no back education)
Number of subjects: 398
Study 14871286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 44
Study 14871286 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 44
Study 11702917 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity cycling (maximal 90-second sprint)
Number of subjects: 10
Study 11702917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (60 rpm equated for total work)
Number of subjects: 10
Study 11702917 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control bout)
Number of subjects: 10
Study 10784465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 210
Study 10784465 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (25-100 mg/day)
Number of subjects: 210
Study 10784465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 210
Study 10784465 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 210
Study 10784465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 210
Study 8627437 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational pneumococcal conjugate vaccine
Number of subjects: 25
Study 8627437 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed pneumococcal polysaccharide vaccine (given as a booster)
Number of subjects: 25
Study 8627437 — intervention group
Group type: COMPARATOR
Intervention: Licensed pneumococcal polysaccharide vaccine (given as a primary injection to control group)
Number of subjects: 25
Study 1456565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3 (steady-state)
Number of subjects: 23
Study 1456565 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular exposure pattern (0.24 ppm O3)
Number of subjects: 23
Study 1456565 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state O3 exposure
Number of subjects: 23
Study 1456565 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 23
Study 6324710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1,200 mg/day orally)
Number of subjects: 11
Study 6324710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/day orally)
Number of subjects: 11
Study 6324710 — intervention group
Group type: COMPARATOR
Intervention: Warfarin sodium (1.5 mg/kg)
Number of subjects: 11
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-suicidal self-injury (NSSI)
Number of subjects: 107
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempts
Number of subjects: 107
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: NSSI frequency
Number of subjects: 107
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: NSSI severity
Number of subjects: 107
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity and depression
Number of subjects: 107
Study 28718985 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increase in NSSI frequency and severity
Number of subjects: 107
Study 29857165 — intervention group
Group type: COMPARATOR
Intervention: Deep dry needling (DDN) with no local twitch responses (LTRs) elicited (control group)
Number of subjects: 120
Study 29857165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with 4 local twitch responses (LTRs) elicited
Number of subjects: 120
Study 29857165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with 6 local twitch responses (LTRs) elicited
Number of subjects: 120
Study 29857165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) until no more local twitch responses (LTRs) were elicited
Number of subjects: 120
Study 29857165 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups receiving DDN
Number of subjects: 120
Study 26778629 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz rTMS over the left dorsolateral prefrontal cortex
Number of subjects: 35
Study 26778629 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 35
Study 24112717 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with programmed parameters including higher detection rates, longer detection intervals, empiric antitachycardia pacing (ATP), and optimized supraventricular tachycardia (SVT) discriminators.
Number of subjects: 1670
Study 24112717 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 1670
Study 24112717 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional parameters.
Number of subjects: 1670
Study 24112717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1670
Study 22782416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus folinic acid (20 mg/m2 of folinic acid via IV bolus followed by 425 mg/m2 of fluorouracil via IV bolus, administered 1 to 5 days every 28 days)
Number of subjects: 428
Study 22782416 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2 IV infusion once a week for 3 of every 4 weeks for 6 months)
Number of subjects: 428
Study 22782416 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 428
Study 20025837 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1623
Study 20025837 — intervention group
Group type: COMPARATOR
Intervention: No MRI
Number of subjects: 1623
Study 16829196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (holding ice cubes in the oral cavity before, during, and after 5FU infusion)
Number of subjects: 76
Study 16829196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy)
Number of subjects: 76
Study 16829196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 76
Study 15854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 12
Study 15854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Malic acid
Number of subjects: 12
Study 15854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 12
Study 15854177 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 15854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid followed by citric acid
Number of subjects: 12
Study 12362144 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from non-professional volunteers
Number of subjects: 2
Study 12362144 — intervention group
Group type: COMPARATOR
Intervention: Conventional child health services
Number of subjects: 2
Study 9883001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan associated chest pain (cases)
Number of subjects: 129
Study 9883001 — intervention group
Group type: COMPARATOR
Intervention: No chest pain after sumatriptan (controls)
Number of subjects: 129
Study 7878172 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (could press a switch to stop the noise)
Number of subjects: 0
Study 7878172 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive group (yoked passive subjects received the same noises with no control)
Number of subjects: 0
Study 7878172 — intervention group
Group type: COMPARATOR
Intervention: Control group (yoked control group heard a soft tone following cue offset)
Number of subjects: 0
Study 2368892 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2% with adrenaline 1:200,000 plus normal saline 0.01 ml/kg
Number of subjects: 30
Study 2368892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:200,000 plus fentanyl 1.0 microgram/kg
Number of subjects: 30
Study 30797535 — intervention group
Group type: EXPERIMENTAL
Intervention: PrAISED 2 intervention
Number of subjects: 0
Study 30797535 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28279168 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 210
Study 28279168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 210
Study 25776532 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, goal-directed therapy (EGDT) - a 6-hour resuscitation protocol
Number of subjects: 1260
Study 25776532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1260
Study 25776532 — intervention group
Group type: EXPERIMENTAL
Intervention: EGDT
Number of subjects: 1260
Study 25885732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional nasal packing (Group NP)
Number of subjects: 90
Study 25885732 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed endotracheal tube (UA group)
Number of subjects: 90
Study 25885732 — intervention group
Group type: COMPARATOR
Intervention: Bilateral nasal airway (BA group)
Number of subjects: 90
Study 21853765 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (gymnastics, dancing, walking) for 8 weeks, 3 days per week
Number of subjects: 82
Study 21853765 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacotherapy (Fluoxetine 20 mg)
Number of subjects: 82